Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02190279 · ClinicalTrials.gov registry record · Early Phase 1
18F-DCFBC PET/CT in Prostate Cancer
A Early Phase 1 study of Prostate Cancer and Prostatic Neoplasms, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Early Phase 1
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT02190279 is a Early Phase 1 study of Prostate Cancer and Prostatic Neoplasms that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 116 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02190279, a Early Phase 1 study of Prostate Cancer and Prostatic Neoplasms, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer. Researchers want to test a radiotracer called N-\[N-\[(S)-1,3-dicarboxypropyl\]carbamoyl\]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) (18F-DCFBC). Objective: \- To see if the radiotracer 18F-DCFBC can identify sites of prostate cancer in the body. Eligibility: \- Men ages 18 and over with prostate cancer. The cancer must be newly diagnosed, have relapsed, or has spread outside the prostate. Design: * Participants will be screened with physical exam and medical history. They will give a blood sample. * Participants will be divided into three groups. Group 1: people with cancer only in the prostate scheduled for surgical prostate removal or biopsy at National Institutes of Health (NIH). Group 2: people who had their prostate removed or had radiation therapy and now have a rising prostate-specific antigen (PSA) without other signs of disease. Group 3: people whose cancer has spread to other areas of the body. * Participants will have 18F-DCFBC injected into a vein then imaged in a positron emission tomography (PET)/computed tomography (CT) camera. During the scans, they will lie on their back on the scanner table. * Group 1 will have a magnetic resonance imaging (MRI) scan. A tube will be placed in the rectum. Coils may be wrapped around the outside of the pelvis. Participants will have a contrast agent injected through an intravenous line. * Group 3 will have another PET/CT scan with a different radiotracer, 18F NaF, within 21 days of the 18F-DCFBC scan to look for prostate cancer in the bone. * Group 3 will repeat the two PET/CT scans 4-6 months after the initial scans. * A few days after each scan, participants will be contacted for follow-up.
Conditions Studied
Interventions
- DRUG 18F DCFBC
- DRUG Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2014-07-12 |
| Est. Completion | 2018-01-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02190279
The ClinicalTrials.gov registry entry for NCT02190279 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which 18F DCFBC is the first listed.
NCT02190279 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT02190279 about?
NCT02190279 is a clinical study titled "18F-DCFBC PET/CT in Prostate Cancer". Background: \- Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer. Researchers want to test a radiotracer called N-\[N-\[(S)-1,3-dicarboxypropyl\]carbamoyl\]-4-(18)F-fluorobenzyl-L-cysteine ((...
What is the current status of trial NCT02190279?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 116 participants. The study started on 2014-07-12. Estimated completion is 2018-01-11.
What conditions does trial NCT02190279 study?
This clinical trial studies the following conditions: Prostate Cancer, Prostatic Neoplasms.
What interventions are being tested in trial NCT02190279?
The interventions under investigation include: 18F DCFBC (DRUG), Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT) (DRUG).
Who is sponsoring clinical trial NCT02190279?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02190279 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
RECRUITING · Early Phase 1
-
Pilot Study of (MR) Imaging with Pyruvate (13C) to Detect High Grade Prostate Cancer
RECRUITING · Early Phase 1
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients
RECRUITING · Early Phase 1
-
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
RECRUITING · Early Phase 1
-
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
ACTIVE NOT RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.